Search the Newsreel

Diabetes and weight-management products using Alina gain European authorizations

Stevanato Group's Alina® pen injector platform has received marketing authorizations in multiple European countries for liraglutide-based combination products used in diabetes and weight management. The approvals for Alina® 30 and Alina® 50 variants highlight the growing demand for injectable therapies, particularly GLP-1 treatments, and …

Stevanato Group Announces Marketing Authorizations for Liraglutide-Based Combination Products Incorporating Alina Pen Injector in Multiple European Countries

Stevanato Group announced that its liraglutide-based combination products, incorporating the proprietary Alina pen injector, have received marketing authorizations in Europe. These authorizations cover both Alina 30 for diabetes and Alina 50 for weight management, supporting the growing demand for injectable therapies like GLP-1 treatments. …

Stevanato Group SpA (STVN) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Stevanato Group SpA (STVN), listing major institutional holders and their respective proportions. Key shareholders include Conestoga Capital Advisors, LLC, Neuberger Berman, LLC, and T. Rowe Price Investment Management, Inc. The report also provides a breakdown of shareholder …

Stevanato Group Spa (STVN) Q1 2023 Earnings Report - Results, Call & Slides

Stevanato Group (STVN) reported its Q1 2023 earnings, missing both EPS and revenue estimates. The company posted an actual EPS of $0.13 against a consensus of $0.14, and revenue of $255.35M compared to an expected $267.16M, though still achieving a YoY revenue growth of …

STVN|Stevanato Group SpA|Price:19.390|Chg%:+0.020

Stevanato Group SpA (STVN) is experiencing healthy fundamentals and high growth potential, with its valuation considered fairly valued within the Healthcare Equipment & Supplies industry. The stock is rated as a "Buy" by multiple analysts, with a target price of 25.175, indicating a significant …

Price-Driven Insight from (STVN) for Rule-Based Strategy

This article provides a price-driven insight for Stevanato Group S.p.a. (NASDAQ: STVN) based on AI models from Stock Traders Daily. It highlights near-term weak sentiment, no clear price positioning signal, and compelling upside potential due to a lack of resistance levels. The report also …

Stevanato Group (STVN) Bank of America Global Healthcare Conference 2026 Summary

Stevanato Group (STVN) presented at the Bank of America Global Healthcare Conference 2026, highlighting its long-term customer partnerships due to high switching costs and regulatory integration, driving strong organic growth through high-value solutions like Nexa syringes. The company emphasized its growth drivers in biologics …

Stevanato Group to Report Second Quarter 2026 Financial Results on August 4, 2026

Stevanato Group S.p.A. announced it will release its second-quarter 2026 financial results on Tuesday, August 4, 2026, at 6:30 a.m. EDT. The company will also host a conference call and webcast at 8:30 a.m. EDT on the same day to discuss the results, with …

Stevanato Group schedules Aug. 4 results webcast at 8:30 a.m.

Stevanato Group (STVN) Investor presentation Summary

Stevanato Group (STVN) presented an investor summary highlighting its operational excellence, market leadership, and strong financial performance. The company has a global footprint, a high-value solutions (HVS) portfolio driving significant revenue growth, and is benefiting from secular tailwinds in the biopharma industry. Future guidance …

Stevanato Group S.p.A. $STVN Stock Holdings Lifted by Van Berkom & Associates Inc.

Van Berkom & Associates Inc. significantly increased its stake in Stevanato Group S.p.A. (NYSE:STVN) by 2,944.2% in the first quarter, now holding 170,994 shares valued at $2.35 million. This move comes despite the company missing Q1 earnings estimates, though revenue rose 6.6% year-over-year. Analysts …

Roubaix Capital LLC Has $5.30 Million Holdings in Stevanato Group S.p.A. $STVN

Roubaix Capital LLC significantly increased its stake in Stevanato Group S.p.A. (NYSE:STVN) by 96.6% in the first quarter, now holding 385,316 shares valued at $5.3 million. Despite Stevanato Group missing Q1 EPS expectations, analysts maintain a constructive outlook, with recent upgrades and an outperform …

STVN Q1 2026 Earnings: EPS Beats Estimates, Stock Declines Amid Lack of Revenue Detail - Earnings Deceleration Risk

Stevanato Group (STVN) Earnings Date and Reports 2026

Stevanato Group (STVN) Q1 Earnings and Revenues Beat Estimates

Stevanato Group Delivers 7% Revenue Growth (9% at Constant Currency) for Fiscal Year 2025, Including Record Revenue from High-Value Solutions and Expanded Margins

Here's What Analysts Are Forecasting For Stevanato Group S.p.A. (NYSE:STVN) After Its Second-Quarter Results